STOCKS TELEGRAPH

Tag: Aptevo Therapeutics

  • 3 Stocks That Could Move Soon: Cardiol Therapeutics (CRDL), Aptevo Therapeutics (APVO), OneMedNet (ONMD)

    3 Stocks That Could Move Soon: Cardiol Therapeutics (CRDL), Aptevo Therapeutics (APVO), OneMedNet (ONMD)

    The biotechnology sector continues to attract investor attention as clinical-stage companies advance innovative therapies targeting major unmet medical needs. With ongoing clinical trials, regulatory developments, and expanding market opportunities, investors remain focused on companies demonstrating strong scientific progress and long-term commercial potential.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) continues to advance its lead cardiovascular therapy at a time when inflammation-focused treatment strategies are receiving growing attention across the biotech sector. As investors evaluate emerging cardiovascular companies, late-stage clinical execution and differentiated science remain important drivers of long-term valuation potential.

    Market Momentum

    As of May 27, 2026, CRDL closed at $1.28, down 1.54%, with trading volume of 330,143 shares compared to an average volume of 689,388 shares. The company currently maintains a market capitalization of $147.548M and a beta of 0.43, reflecting relatively moderate volatility for a clinical-stage biotech company. Shares continue trading within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.29 suggests substantial upside potential tied to future clinical and regulatory milestones.

    Late-Stage Development Progress

    Cardiol’s Phase III MAVERIC trial evaluating CardiolRx™ for recurrent pericarditis remains the company’s primary near-term catalyst. The randomized, double-blind, placebo-controlled study has surpassed 75% patient enrollment and was designed in collaboration with the U.S. Food and Drug Administration following encouraging Phase II discussions.

    Clinical Foundation

    Earlier clinical findings demonstrated reductions in pericarditis-related pain, inflammation, and recurrence frequency while also showing favorable safety and tolerability outcomes. These results have helped strengthen the clinical rationale supporting CardiolRx™ as a potential treatment option for patients suffering from recurrent inflammatory heart disease.

    Outlook

    With enrollment continuing to advance and earlier clinical data supporting the therapy’s development profile, Cardiol appears increasingly well-positioned as it moves toward future regulatory discussions and potential commercialization opportunities.

    Aptevo Therapeutics Inc (APVO)

    Aptevo Therapeutics Inc (NASDAQ: APVO) started the day on May 27, 2026, with a price decrease of -1.02% at $4.84. During the day, the stock rose to $4.94 and sank to $4.42. Taking a long-term approach, APVO posted a 52-week range of $3.80-$235.98.

    The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 89.05%. Meanwhile, its Annual Earnings per share during the time was 89.05%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is 72.35%. This publicly-traded company’s shares outstanding now amount to $1.25 million, simultaneously with a float of $1.25 million. The organization now has a market capitalization of $6.03 million.

    OneMedNet Corp (ONMD)

    As of May 27, 2026, OneMedNet Corp (NASDAQ: ONMD) started slowly as it slid -3.94% to $0.85. During the day, the stock rose to $0.88 and sank to $0.85. Taking a long-term approach, ONMD posted a 52-week range of $0.31-$4.22.

    This publicly-traded company’s shares outstanding now amount to $52.79 million, simultaneously with a float of $14.89 million. The organization now has a market capitalization of $46.27 million. Its Quick Ratio in the last reported quarter now stands at 0.27. Another valuable indicator worth pondering is a publicly-traded company’s price-to-sales ratio for the trailing twelve months, which is currently 35.05.

  • Aptevo (APVO) Gains Pre-Hour Boost On Encouraging AML Treatment Efficacy

    Aptevo (APVO) Gains Pre-Hour Boost On Encouraging AML Treatment Efficacy

    Aptevo Therapeutics Inc. (NASDAQ: APVO) is witnessing a substantial surge in share value during Wednesday’s pre-market session, rising 152.84% to $7.13. The stock’s sharp increase follows the company’s announcement of updated clinical-trial data.

    Clinical Breakthrough

    Aptevo Therapeutics shared data from its Phase 1b/2 RAINIER trial of mipletamig—a first-in-class CD123 x CD3 bispecific antibody being tested in combination with standard therapies venetoclax and azacitidine (ven/aza) in patients newly diagnosed with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy.

    Exceptional Remission Rates in Frontline AML

    According to Aptevo, the combination therapy demonstrated remission in 85% of evaluable frontline AML patients across two studies. This rate notably surpasses outcomes seen in comparator trials such as the Viale A study, which evaluated ven/aza alone.

    The first two patient cohorts showed encouragingly no signs of cytokine release syndrome (CRS), a common and severe adverse effect in many immunotherapies. Nearing full enrollment is Cohort 3, which is evaluating the greatest dosage level to yet.

    Strategic Innovation Behind Mipletamig

    The high efficacy and favorable safety data are credited to Aptevo’s proprietary CD3 engineering platform. Mipletamig uniquely utilizes the CRIS-7 binding domain, a strategic design intended to reduce cytokine-driven toxicity while maintaining potent anti-cancer activity.

    This engineering approach not only underpins mipletamig’s current success but is also expected to strengthen future candidates in Aptevo’s pipeline, such as its preclinical prostate cancer therapy, APVO442.

    Redefining AML Therapy for Unfit Patients

    AML is a particularly aggressive blood cancer, with limited options and generally poor outcomes for elderly or medically unfit patients. Aptevo’s findings suggest that mipletamig may offer a new, more effective, and better-tolerated frontline therapy.

    With 85% remission achieved—three of which were in patients with high-risk genetic profiles—Aptevo (APVO) positions mipletamig as a promising candidate to redefine treatment paradigms and elevate standards of care in a historically underserved population.

  • Aptevo (APVO) Sees Significant Market Rally After Equity Offering

    Aptevo (APVO) Sees Significant Market Rally After Equity Offering

    Aptevo Therapeutics Inc. (NASDAQ: APVO) shares are on a remarkable surge of 44.98% as of the last check today, reaching $2.01. This sharp increase in APVO stock follows a pivotal equity offering move by the biotechnology company, reinforcing investor confidence in its ongoing strategic initiatives.

    Registered Direct Offering

    Definitive securities purchase agreements for the issue of 1,764,710 shares of Aptevo Therapeutics’ common stock in a registered direct offering have been concluded. Concurrently, APVO has issued warrants to purchase up to 3,529,420 additional shares in a private placement. The total purchase price for each share and associated warrant is fixed at $1.19.

    The warrants will be exercisable after shareholder approval and will be valid for five years after the initial exercise date. They have an exercise price of $1.19 per share. With the fulfillment of standard closing conditions, the offering is expected to close on or around April 4, 2025.

    Before subtracting placement agency fees and related offering expenses, Aptevo expects to make around $2.1 million in gross proceeds. The money will go toward working capital, basic business needs, and the ongoing clinical development of its pharmaceutical prospects.

    Positive Clinical Advancements

    In a significant clinical advancement, Aptevo Therapeutics recently reported that two additional frontline acute myeloid leukemia (AML) patients have achieved remission within 30 days of treatment in its RAINIER dose optimization trial. The study evaluates the effectiveness of mipletamig in combination with the standard of care for patients unfit for intensive chemotherapy.

    The latest data reinforces the promising results from Cohort 1 and the prior dose expansion trial, where all frontline patients attained remission. With these interim findings, mipletamig has demonstrated a compelling overall remission rate of 90% among frontline patients.

    Future Prospects

    Aptevo Therapeutics continues to see very positive remission rates in Cohort 2 of the RAINIER study, which has now crossed the halfway point. These findings highlight the potential benefits of mipletamig for AML patients who would ordinarily require venetoclax plus azacitidine as the conventional treatment but are not eligible for intense chemotherapy.

    Aptevo is still committed to proving the effectiveness of mipletamig’s distinct mode of action in combination treatment. This strategy supports APVO’s efforts to develop cutting-edge treatments for AML and shows promise, especially for older patients with few therapy alternatives.

  • Aptevo Therapeutics (APVO) Sees Spectacular Rise Push on to Pre-market Session

    Aptevo Therapeutics Inc. (NASDAQ: APVO) experienced a whirlwind of activity on Wednesday, with its stock soaring an impressive 35%. Yet, the excitement didn’t stop there. In the early premarket hours on Thursday, APVO witnessed an additional staggering leap of 49%, reaching a high of $1.43.

    What’s Driving the Surge?

    Despite the lack of apparent news fueling this surge, speculations abound. Many investors are speculating about potential insider accumulation, hinting at undisclosed positive catalysts on the horizon. This mystery behind the surge has left some wary, fearing an impending profit-taking dip in the coming days. However, for now, bullish sentiment prevails as investors ride the wave of optimism.

    Aptevo Therapeutics: Pioneering Immunotherapies

    Aptevo Therapeutics, Inc. stands as a beacon in the realm of biotechnology, particularly in the field of cancer treatment. The company focuses on developing innovative immunotherapies to combat various forms of cancer. Its robust pipeline includes promising candidates like APVO436, ALG.APV-527, APVO603, and APVO442, developed leveraging cutting-edge ADAPTIR modular protein platform technology.

    The recent surge in APVO’s stock value coincides with significant updates shared by the company’s CEO in a letter to shareholders. The letter highlighted the remarkable progress made in advancing clinical programs, notably the encouraging durability of remission data from the APVO436 Phase 1b dose expansion trial. This data, showcasing impressive patient responses and safety profiles, underscores the potential of APVO436 to enhance the standard of care for Acute Myeloid Leukemia (AML) patients.

    Moreover, ongoing trials evaluating ALG.APV-527 for the treatment of multiple solid tumor types have shown promising early results. Notably, the drug’s ability to induce stable disease in heavily pretreated breast cancer patients signifies a significant breakthrough in cancer therapeutics.

    In Conclusion

    As Aptevo Therapeutics continues its pioneering work in cancer immunotherapy, investors eagerly anticipate further developments in its clinical programs. With promising candidates like APVO436 and ALG.APV-527 demonstrating encouraging results, the company remains at the forefront of innovation in cancer treatment.

    As the market awaits upcoming trial milestones and potential positive catalysts, optimism surrounding Aptevo Therapeutics continues to grow, fueled by the promise of creating a brighter future for cancer patients worldwide.

  • Aptevo Therapeutics (APVO) Faces Sharp Decline in Premarket Trading

    Aptevo Therapeutics Inc. (NASDAQ: APVO) experienced a tumultuous Wednesday as its stock price took a staggering 26% nosedive, plummeting from $3.26 to $2.40. However, the woes for investors didn’t end there.

    In the early premarket hours on Thursday, APVO continued its downward spiral, plunging a further 42% to as low as $1.40. The drastic drop was accompanied by a surge in trading volume, which doubled the average. This sudden and severe decline has left many investors scrambling to unload their APVO holdings.

    Pipeline Updates

    The sharp downturn coincides with significant updates from the company regarding its pipeline. Aptevo Therapeutics, Inc. is a clinical-stage biotechnology firm focused on developing novel immunotherapies for cancer treatment. Its pipeline includes promising candidates such as APVO436, ALG.APV-527, APVO603, and APVO442, developed using innovative modular protein platform technologies.

    Recent announcements have highlighted advancements in clinical programs and preclinical developments:

    ALG.APV-527 Phase 1 Trial

    • A patient transitioned from progressive disease to long-lasting stable disease, marking a significant milestone in cancer treatment research.
    • The trial is more than 50% enrolled, with dosing in cohort five (of six) imminent.

    Phase 1b/2 Trial for APVO436

    • Scheduled to commence in the first half of 2024.
    • Aimed at evaluating APVO436 for the treatment of acute myeloid leukemia (AML) in combination therapy.

    APVO711 Preclinical Progress

    • Promising results indicate potential for targeting a broad range of solid tumors.
    • APVO711 shows the dual mechanism of action functionality, offering new hope for patients in need of more effective treatments.

    Dr. Dirk Huebner, Chief Medical Officer at Aptevo, expressed optimism about ALG.APV-527’s potential, citing the uncommon but therapeutically promising outcome observed in the trial. Additionally, the company is poised to initiate a Phase 1b/2 trial for APVO436 in the first half of 2024, further underscoring its commitment to advancing cancer therapeutics.

    Furthermore, APVO711, a bispecific checkpoint inhibitor, has shown promising preclinical results, with the company’s robust financial position providing a solid foundation for future developments. With approximately $16 per share in cash reserves, Aptevo is well-positioned to navigate the challenges and opportunities in the biotechnology landscape.

    Conclusion

    In conclusion, while Aptevo Therapeutics Inc. grapples with a significant decline in premarket trading, its commitment to advancing innovative cancer therapies remains unwavering. Investors are closely monitoring developments in its pipeline, recognizing the potential for long-term growth amid the current market volatility.